Predictive and prognostic significance of sodium levels in
patients with NSCLC treated by Erlotinib

J 2014

Predictive and prognostic significance of sodium levels in patients with NSCLC treated by Erlotinib

SVATON, Martin; Ondrej FIALA; Milos PESEK; Frantisek BRUHA; Petr MUKENSNABL et al.

Základní údaje

Originální název

Predictive and prognostic significance of sodium levels in patients with NSCLC treated by Erlotinib

Autoři

SVATON, Martin; Ondrej FIALA; Milos PESEK; Frantisek BRUHA; Petr MUKENSNABL; Jaroslav RACEK; Marek MINARIK a Zbyněk BORTLÍČEK

Vydání

Anticancer Research, Athens, International Institute of Anticancer Research, 2014, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.826

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00078688

Organizační jednotka

Lékařská fakulta

UT WoS

000346689700077

Klíčová slova anglicky

Hyponatremia; NSCLC; OS; PFS; Predictive marker; Prognosis

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 4. 2015 13:41, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Background: Hyponatremia is a well-known phenomenon in cancer patients. The aim of our retrospective study was to assess the relationship of natremia levels to predict treatment with erlotinib and also to assess the prognosis of patients with hyponatremia. Patients and Metods: We analyzed data of 544 patients with advancedstage non-small cell lung cancer (NSCLC) treated with erlotinib. Results: Hyponatremia was measured in 21.5 % of patients before treatment with erlotinib. We found a significant increase in the effectiveness of treatment with erlotinib in patients with normal levels of sodium to hyponatremic patients. Progression-free survival (PFS) and overall survival (OS) were also significantly higher in patients with normal natremia. Multivariate Cox model analysis demonstrated that natremia was an independent factor for PFS and OS. Conslusion: We reported hyponatremia not only as a prognostic marker in NSCLC patients but also as predictive marker of erlotinib treatment efficacy, being an independent factor at the present large retrospective study. Its possible effect in clinical practice is bigger thanks the simple possibility of testing of hyponatremia and the low cost of this biomarker.

Citovat

SVATON, Martin; Ondrej FIALA; Milos PESEK; Frantisek BRUHA; Petr MUKENSNABL; Jaroslav RACEK; Marek MINARIK a Zbyněk BORTLÍČEK. Predictive and prognostic significance of sodium levels in patients with NSCLC treated by Erlotinib. Anticancer Research. Athens: International Institute of Anticancer Research, 2014, roč. 34, č. 12, s. 7461-7465. ISSN 0250-7005.

@article{1218637,
   author = {Svaton, Martin and Fiala, Ondrej and Pesek, Milos and Bruha, Frantisek and Mukensnabl, Petr and Racek, Jaroslav and Minarik, Marek and Bortlíček, Zbyněk},
   article_location = {Athens},
   article_number = {12},
   keywords = {Hyponatremia; NSCLC; OS; PFS; Predictive marker; Prognosis},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   title = {Predictive and prognostic significance of sodium levels in patients with NSCLC treated by Erlotinib},
   volume = {34},
   year = {2014}
}

TY  - JOUR
ID  - 1218637
AU  - Svaton, Martin - Fiala, Ondrej - Pesek, Milos - Bruha, Frantisek - Mukensnabl, Petr - Racek, Jaroslav - Minarik, Marek - Bortlíček, Zbyněk
PY  - 2014
TI  - Predictive and prognostic significance of sodium levels in patients with NSCLC treated by Erlotinib
JF  - Anticancer Research
VL  - 34
IS  - 12
SP  - 7461-7465
EP  - 7461-7465
PB  - International Institute of Anticancer Research
SN  - 02507005
KW  - Hyponatremia
KW  - NSCLC
KW  - OS
KW  - PFS
KW  - Predictive marker
KW  - Prognosis
N2  - Background: Hyponatremia is a well-known phenomenon in cancer patients. The aim of our retrospective study was to assess the relationship of natremia levels to predict treatment with erlotinib and also to assess the prognosis of patients with hyponatremia. Patients and Metods: We analyzed data of 544 patients with advancedstage non-small cell lung cancer (NSCLC) treated with erlotinib. Results: Hyponatremia was measured in 21.5 % of patients before treatment with erlotinib. We found a significant increase in the effectiveness of treatment with erlotinib in patients with normal levels of sodium to hyponatremic patients. Progression-free survival (PFS) and overall survival (OS) were also significantly higher in patients with normal natremia. Multivariate Cox model analysis demonstrated that natremia was an independent factor for PFS and OS. Conslusion: We reported hyponatremia not only as a prognostic marker in NSCLC patients but also as predictive marker of erlotinib treatment efficacy, being an independent factor at the present large retrospective study. Its possible effect in clinical practice is bigger thanks the simple possibility of testing of hyponatremia and the low cost of this biomarker.
ER  -

SVATON, Martin; Ondrej FIALA; Milos PESEK; Frantisek BRUHA; Petr MUKENSNABL; Jaroslav RACEK; Marek MINARIK a Zbyněk BORTLÍČEK. Predictive and prognostic significance of sodium levels in patients with NSCLC treated by Erlotinib. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2014, roč.~34, č.~12, s.~7461-7465. ISSN~0250-7005.

Přehled o publikaci